Healthcare Equipment and Supplies
Company Overview of Verinata Health, Inc.
Verinata Health, Inc. develops non-invasive tests for the early identification of fetal chromosomal abnormalities. It develops non-invasive alternatives for maternal and fetal health; and non-invasive verifi prenatal tests to detect Turner syndromes. The company has a strategic agreement with PerkinElmer Inc. Verinata Health, Inc. was formerly known as Artemis Health, Inc. and changed its name to Verinata Health, Inc. in April 2011. The company was founded in 2002 and is based in Redwood City, California. As of February 21, 2013, Verinata Health, Inc. operates as a subsidiary of Illumina Inc.
800 Saginaw Drive
Redwood City, CA 94063
Founded in 2002
Key Executives for Verinata Health, Inc.
Co-Founder, President and Director
Vice President of Finance and Administration
Senior Vice President of Research and Development
Senior Director of Clinical Research
Compensation as of Fiscal Year 2014.
Verinata Health, Inc. Key Developments
Illumina, Inc. and Sequenom, Inc. Agree to Settle All Pending Infringement Claims and Other Disputes Between Sequenom and Verinata Health, Inc
Dec 3 14
Illumina Inc. and Sequenom Inc. announced they have agreed to settle all pending infringement claims and other disputes between Sequenom and Verinata Health Inc. The parties will pool their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference proceedings. Under the agreement, Illumina will have exclusive worldwide rights to utilize the pooled intellectual property to develop and sell in-vitro diagnostic kits for NIPT and to license third-party laboratories wishing to develop and sell their own laboratory-developed NIPT tests under the collection of pooled patents. In addition, Sequenom and Illumina will each have rights to utilize all pooled patents to develop and sell their own respective laboratory-developed NIPT tests. The parties will share the revenue from the patent pool and Illumina will pay Sequenom a royalty on sales of in-vitro diagnostic kits for NIPT. Illumina will make a $50 million upfront payment to Sequenom as part of the overall agreement, as well as certain ongoing commitments for payments to Sequenom from the patent pool structure through 2020.
Verinata Health's verifi(R) Prenatal Test Expanded to Include Option to Test for Fetal Aneuploidy in Twin Pregnancies
Oct 14 13
Illumina, Inc. announced that Verinata Health will offer a new test option for its non-invasive verifi(R) prenatal test. Physicians will now be able to use the verifi(R) prenatal test for women pregnant with twins through natural or assisted reproductive methods. The verifi(R) prenatal test for twins can detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and the presence of a Y chromosome in the fetuses. Verinata validated its algorithms specifically for twins through an analysis of 115 maternal plasma samples from twin pregnancies, with all instances of aneuploidy detected. Of the 115 samples, the verifi(R) prenatal test with twins option correctly detected all cases of Down syndrome (trisomy 21) and Edwards syndrome (trisomy 18) in the samples, as well as all samples in which the Y-chromosome was present. The rate of twins increased 76% from 1980 to 2009. As women age, they are more likely to release more than one egg per menstrual cycle and as such, women over 30 account for about one third of the increase in twin pregnancies.
Verinata Health Announces Agreement with Teva Pharmaceutical Industries for Medical Data to Commercialize the Verifi Prenatal Test in Israel
Jul 1 13
Illumina, Inc. announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, for the commercialization of the verifi(R) non-invasive prenatal test in Israel. The MOR Institute for Medical Data Ltd., through its relationship with Teva, will provide the verifi(R) prenatal test to customers of Clalit Health Services who are at high risk of having a fetus with a chromosomal abnormality. The MOR Institute, will also establish a 9,000-patient clinical outcomes registry to collect performance data and will share the data with Verinata. Under the terms of the five-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the verifi(R) prenatal test in Israel. All tests will be run in Verinata Health's CLIA-certified laboratory in California. Clalit Health Services will provide reimbursement for the verifi(R) prenatal test through supplemental insurance.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|